Elara: Four legs against hypoxia

Elara Pharmaceuticals GmbH is developing four new chemical classes of orally available hypoxia signaling inhibitors that it thinks could treat cancer more effectively and safely than first generation inhibitors in the clinic.

Elara is collaborating with the myeloma center at UniversitätsKlinikum Heidelberg on IND-enabling studies of an unnamed lead compound to treat multiple myeloma (MM). The company expects to file an IND by the end of 2010 and enter Phase I testing early in 2011...